CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,817 | -19.3% | 723 | -0.1% | 0.00% | – |
| Q2 2023 | $40,646 | +24.5% | 724 | +0.3% | 0.00% | – |
| Q1 2023 | $32,657 | +8.6% | 722 | -2.4% | 0.00% | – |
| Q4 2022 | $30,081 | -38.6% | 740 | -0.4% | 0.00% | -100.0% |
| Q3 2022 | $49,000 | +8.9% | 743 | +0.8% | 0.00% | 0.0% |
| Q2 2022 | $45,000 | +18.4% | 737 | +21.0% | 0.00% | – |
| Q1 2022 | $38,000 | +375.0% | 609 | +443.8% | 0.00% | – |
| Q4 2021 | $8,000 | -38.5% | 112 | 0.0% | 0.00% | – |
| Q3 2021 | $13,000 | 0.0% | 112 | +40.0% | 0.00% | – |
| Q2 2021 | $13,000 | +30.0% | 80 | 0.0% | 0.00% | – |
| Q1 2021 | $10,000 | -16.7% | 80 | 0.0% | 0.00% | – |
| Q4 2020 | $12,000 | – | 80 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |